BioXcel Therapeutics (BTAI) Misses Q3 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioXcel Therapeutics (BTAI) Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders
November 11, 2020 7:07 AM ESTBioXcel Therapeutics, Inc. (BTI or the Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that it has completed its pre-NDA meeting with the FDA for BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders. BXCL501, which received Fast Track designation from the FDA, is the Companys novel, proprietary, orally dissolving, sublingual thin film formulation of dexmedetomidine (Dex). The purpose of the meeting was to discuss the FDAs expectations regarding the content and formatting of the NDA submission... More
